Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mometasone furoate combination MDI 200 · 1 trial · 1 indication
AEs that are considered Related, Severe, and Serious, as determined by the investigator and using specific criteria defined in the protocol, are included in the primary results.
| Arm | Type | Description |
|---|---|---|
| MF/F 200/10 mcg BID | EXPERIMENTAL | - |
| MF/F 400/10 mcg BID | EXPERIMENTAL | - |
| F/SC 250/50 mcg BID | ACTIVE_COMPARATOR | - |
| F/SC 500/50 mcg BID | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| mometasone furoate combination MDI 200/10 mcg BID | DRUG | MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year |
| mometasone furoate combination MDI 400/10 mcg BID | DRUG | MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year |
| Fluticasone/Salmeterol 250/50 mcg BID | DRUG | F/SC 250/50 twice daily for 1 year |
| Fluticasone/Salmeterol 500/50 mcg BID | DRUG | F/SC 500/50 twice daily for 1 year |
Inclusion Criteria: * Subjects of either sex and any race, at least 12 years of age, with a diagnosis of asthma of at least 12 months. * Use of medium or high daily dose of ICS (alone or in combination with long-acting beta-agonist \[LABA\]) for at least 12 weeks prior to Screening and have been on...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Mometasone furoate combination MDI 200 is an investigational inhaled therapy being developed for the treatment of asthma. It is a fixed-dose combination product delivered by metered dose inhaler and is intended for patients with persistent asthma, including those previously treated with inhaled glucocorticosteroids.
Mometasone furoate combination MDI 200 is being developed by Organon & Co., which trades on the New York Stock Exchange under the ticker OGN. Organon is the sponsor responsible for the clinical development program for this asthma candidate.
Mometasone furoate combination MDI 200 is in Phase 3 clinical development for asthma. The program includes one completed Phase 3 trial. The drug is investigational and has not been approved by the FDA for any indication.
Mometasone furoate combination MDI 200 has been studied in one Phase 3 trial, NCT00379288, titled Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139). The trial is completed and enrolled 404 participants aged 12 years and older.
The completed Phase 3 trial NCT00379288 was a randomized, active-controlled study of 404 participants with persistent asthma who had previously been treated with inhaled glucocorticosteroids. It was not double-blind and enrolled patients aged 12 years and older of all sexes. Healthy volunteers were not included.